Enlivex notifies availability of press release on FDA RMAT designation for Allocetra in knee osteoarthritis - ENLV News | RalliesEnlivex notifies availability of press release on FDA RMAT designation for Allocetra in knee osteoarthritis
E
ENLV• FDA RMAT designation for Allocetra in knee osteoarthritis
- Enlivex press release posted on FDA RMAT designation for Allocetra in symptomatic age-related knee osteoarthritis for patients aged 64+.
- RMAT status may speed development via closer FDA engagement, accelerated approval pathways, priority review.
- Phase IIb randomized trial targets 182 patients in the US, EU; top-line data expected by end-Q2 2027.
•
